Champions Oncology, Inc. (CSBR) Stock

Champions Oncology, Inc. (CSBR) is a Healthcare stock trading at $6.71 (as of 2026-06-17), with a market capitalization of $81.10M and a trailing P/E of -38.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Champions Oncology, Inc. provides technology and software offerings aimed at personalizing oncology drug development and use in the United States. Its Tumorgraft Technology Platform uses implanted human tumors in immune-deficient mice, supported by Translational Oncology Solutions for pharmaceutical and biotechnology customers and the Lumin Bioinformatics subscription software platform for research and clinical study-derived data.

Valuation — source: SEC EDGAR (first-party)
Price	$6.71
Market Cap	$81.10M
P/E Ratio	-38.2
EV / EBITDA	-73.9
Price / Book	20.62
Price / Sales	1.56
DCF Value (model)	$9.36
DCF Upside vs Price	39.4%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$56.94M
Net Margin	8.3%
Return on Equity	-53.5%
Current Ratio	0.98
Revenue Growth (YoY)	-2.8%
EPS Growth (YoY)	-106.1%
FCF Growth (YoY)	-832.7%

Financial Health — source: SEC EDGAR
Altman Z-Score	0.65 (distress)

Valuation vs Sector & Industry
Stock P/E	-38.2
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-283.1%
vs Industry	-324.7%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BATTERY MANAGEMENT CORP. ($13.92M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Robert Brainin
Employees	210
Country	US
IPO Date	2007-02-02

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-17.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.